Patents Assigned to BIOAGE LABS, INC.
  • Survival prediction using metabolomic profiles
    Patent number: 11881311
    Abstract: In various embodiments, the present description relates to the use of factors related to survival. The methods, compositions and systems described herein may be used to determine factors affecting survival, assess survival risk based on factors related to survival and/or make suggestions to increase the likelihood of survival longer than otherwise predicted.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 23, 2024
    Assignee: BioAge Labs, Inc.
    Inventors: Kristen Patricia Fortney, Yonatan Nissan Donner, Eric Kim Morgen, Jonah Daniel Sinick, Andrew Jarai Ho
  • N-oxide inhibitors of NLRP3 inflammasome
    Patent number: 11787805
    Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: October 17, 2023
    Assignee: BioAge Labs, Inc.
    Inventor: George Hartman
  • Inhibitors of NLRP3 inflammasome
    Patent number: 11708334
    Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: July 25, 2023
    Assignee: BIOAGE LABS, INC.
    Inventors: George Hartman, Paul Humphries, Kevin Edward Leif Wilhelmsen
  • Inhibitors of NLRP3 inflammasome
    Patent number: 11702391
    Abstract: The present disclosure relates to compounds of Formula I: that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: July 18, 2023
    Assignees: BIOAGE LABS, INC., HITGEN, INC.
    Inventors: George Hartman, Xu He, Jia Du, Lifang Zhang, Paul Humphries, Kevin Edward Leif Wilhelmsen
  • RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses Thereof
    Publication number: 20230212252
    Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 6, 2023
    Applicant: BioAge Labs, Inc.
    Inventors: Robert HUGHES, William STROHL
  • RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof
    Patent number: 11535661
    Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: December 27, 2022
    Assignee: BIOAGE LABS, INC.
    Inventors: Robert Hughes, William Strohl
  • RAGE fusion proteins with improved stability and ligand binding affinity and uses thereof
    Patent number: 10913784
    Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: February 9, 2021
    Assignee: BIOAGE LABS, INC.
    Inventors: Robert Hughes, William Strohl